
PsyBio Therapeutics
Developing a portfolio of psychoactive compounds targeted for the treatment of mental health challenges and other disorders.
Market cap
$939k
Enterprise value
$1m
Share price
CAD0.01 PSYB.V
Authorizing premium user...
Developing a portfolio of psychoactive compounds targeted for the treatment of mental health challenges and other disorders.